Developer of oral versions of biologic therapies to be purchased by Intrexon

Biotech player Intrexon ($XON) has signed up to acquire Belgium's ActoGeniX for $60 million. The new addition is a developer of oral meds as an alternative to injectable biologics. Currently, biologic therapies cannot withstand the rigors of the acid in the stomach, so oral versions of the new-era drugs are lacking. "Utilization of living biofactories, whether through adoptive T-cell therapies, autologous fibroblast platforms or food-grade microbes, is one of the principal objects of the engineering of biology, which we aspire to lead at Intrexon," CEO R.J. Kirk said in a statement. "The outstanding team at ActoGeniX is a welcome addition to assist us in this endeavor." More

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.